5/30/2023 0 Comments Tetra bio pharmaTime-HTS processes need to screen millions (and millions) of compounds every year. The magic triangle of HTSįrom “The Future of High-Throughput Screening,” by Mayr L and Fuerst P, for Journal of Biomolecular Screening. It may be comforting to know that even as screening technology improves, and the volume of investigational compounds sitting on deck trends toward infinity, the fundamental requirements for effective HTS remain the same. Keeping HTS effective in the era of big data However, with the rise of ever more complicated modalities such as personalized therapies, biologics, and cell-based therapy, which deal with molecules 10 3-10 13 times larger and more complex than classic small molecule compounds, the volume of compounds that need to be screened has outpaced HTS’s accession. Cost-per-tested entity has steadily declined as screening techniques have become more advanced, require less material per experiment, and employ improved technology. Since its widespread adoption in the 90s, the process has become increasingly efficient. Laboratories investigating small and large molecules, materials, and even cell-based therapies use HTS every day. HTS currently dominates the early discovery landscape. These processes utilize orchestration robotics, liquid handlers, plate readers, informatics applications, and other various software with the goal of rapidly identifying compounds that modulate specific targets, pathways, or cells/organisms. Ultra HTS, or uHTS, is defined as 100,000+ compounds screened per day. HTS is defined as the screening of 10,000-100,000 compounds per day. This staggering attrition rate means companies need to screen compound libraries quickly and accurately. Out of the millions upon millions of compounds that biopharmaceutical companies screen, perhaps only a handful will emerge as potential drug candidates.
0 Comments
Leave a Reply. |